862310-27-8

Basic information

• Product Name: Piperidine, 1-cyclopentyl-4-(4-nitrophenoxy)-
• CAS NO: 862310-27-8
• Molecular Formula: C16H22N2O3
• Molecular Weight: 290.362
• Mol File: 862310-27-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Piperidine, 1-cyclopentyl-4-(4-nitrophenoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperidine, 1-cyclopentyl-4-(4-nitrophenoxy)-(862310-27-8)
• EPA Substance Registry System: Piperidine, 1-cyclopentyl-4-(4-nitrophenoxy)-(862310-27-8)

Safety Data

• Hazardous Substances Data: 862310-27-8(Hazardous Substances Data)

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 148505-45-7 4-(4-nitrophenoxy)piperidine hydrochloride 
• 120-92-3 cyclopentanone 
• 138227-62-0 tert-butyl 4-(4-nitrophenoxy)piperidine-1-carboxylate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 832735-53-2 1-cyclopentyl-4-hydroxypiperidine 
• 162402-39-3 4-(4-nitrophenoxy)piperidine 

Downstream Products

• 862310-29-0 4-((1-cyclopentylpiperidin-4-yl)oxy)aniline 

Relevant articles and documents

Identification of N-phenyl-3-methoxy-4-pyridinones as orally bioavailable H3 receptor antagonists and β-amyloid aggregation inhibitors for the treatment of Alzheimer's disease

Based on our previous work, a series of N-phenyl-3-methoxy-4-pyridinone derivatives were designed as orally bioavailable dual functional agents for therapy of Alzheimer's disease, through introducing alkyloxy moiety into 4-pyridinone ring to avoid the pos

Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity

A series of chemical optimizations guided by in vitro affinity at a histamine H3 receptor (H3R), physicochemical properties, and pharmacokinetics in rats resulted in identification of N-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride (17v, SUVN-G3031) as a clinical candidate. Compound 17v is a potent (hH3R Ki = 8.73 nM) inverse agonist at H3R with selectivity over other 70 targets, Compound 17v has adequate oral exposures and favorable elimination half-lives both in rats and dogs. It demonstrated high receptor occupancy and marked wake-promoting effects with decreased rapid-eye-movement sleep in orexin-B saporin lesioned rats supporting its potential therapeutic utility in treating human sleep disorders. It had no effect on the locomotor activity at doses several fold higher than its efficacious dose. It is devoid of hERG and phospholipidosis issues. Phase-1 evaluation for safety, tolerability, and pharmacokinetics, and long-term safety studies in animals have been successfully completed without any concern for further development.

Fused ring 4-oxopyrimidine derivative

The present invention provides a compound represented by formula (I) below, or a pharmaceutically acceptable salt thereof, which, having histamine H3 receptor antagonist or inverse agonist activity, is useful in the prophylaxis or therapy of metabolic diseases, circulatory diseases, or nervous system diseases. [where, for example, Ar is a divalent group formed by eliminating two hydrogen atoms from benzene, X1 is a nitrogen atom, sulfur atom or oxygen atom, R1 is a 5- to 6-membered heteroaryl group, Ring A is a 5- to 6-membered heteroaryl ring, R2 and R3 are amino groups or alkylamino groups, and X2 is represented by formula (II): (where R4 and R5 are lower alkyl groups, and n is an integer from 2 to 4).]